QRXPHARMA LTD. Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.
Rule 4.7B
Name of entity |
QRxPharma Limited |
ABN | Quarter ended ("current quarter") |
16 102 254 151 | 30 June 2015 |
Cash flows related to operating activities | Current quarter $A'000 | Year to date (12 months) $A'000 | |
1.1 | Receipts from customers | - | - |
1.2 | Payments for (a) staff costs
| (94) - (42) - (364) | (1,906) - (1,873) - (4,450) |
1.3 | Dividends received | - | - |
1.4 | Interest and other items of a similar nature received | 2 | 9 |
1.5 | Interest and other costs of finance paid | - | - |
1.6 | Income taxes refund / (paid) | - | - |
1.7 | Other - Escrow account (deposit) / receipts(i) Other - Cost recoveries Other - Research and development cash incentive received | 169 - 47 | 246 109 47 |
Net operating cash flows | (282) | (7,818) | |
(i) On 4 July 2014 the Company entered into an Escrow Deed arrangement with its then current employees, consultants and the former CEO, covering potential liabilities arising from i) Notice entitlements, ii) Termination payments and where applicable, iii) Retention payments, for an aggregate amount of A$3.6 million. The Company deposited these funds into a bank account under the administration of an escrow agent in accordance with the terms of the Escrow Deed. The escrow cash was principally held in US dollars which appreciated against the Australian dollar over the last 12 months, with a foreign exchange gain of A$0.6 million. Year to date A$3.9 million has been received from the escrow agent in settlement of a significant portion of these liabilities.
Current quarter $A'000 | Year to date (12 months) $A'000 | ||
1.8 | Net operating cash flows (carried forward) | (282) | (7,818) |
Cash flows related to investing activities | - - - - - | - - - (7) - | |
1.9 | Payment for acquisition of:
| ||
1.10 | Proceeds from disposal of:
| - - - - - | - - - - - |
1.11 | Loans to other entities | - | - |
1.12 | Loans repaid by other entities | - | - |
1.13 | Other (Bank Accepted Commercial bills and Term Deposit with maturity greater than 3 months) | - | - |
Net investing cash flows | - | (7) | |
1.14 | Total operating and investing cash flows | (282) | (7,825) |
Cash flows related to financing activities | - | - | |
1.15 | Proceeds from issues of shares, options, etc. | ||
1.16 | Proceeds from sale of forfeited shares | - | - |
1.17 | Proceeds from borrowings | - | - |
1.18 | Repayment of borrowings | - | - |
1.19 | Dividends paid | - | - |
1.20 | Other | - | - |
Net financing cash flows | - | - | |
Net increase (decrease) in cash held | (282) | (7,825) | |
1.21 | Cash at beginning of quarter/year to date | 3,380 | 10,525 |
1.22 | Exchange rate adjustments to item 1.20 | (25) | 373 |
1.23 | Cash at end of quarter | 3,073 | 3,073 |
Current quarter $A'000 | ||
1.24 | Aggregate amount of payments to the parties included in item 1.2 | 12 |
1.25 | Aggregate amount of loans to the parties included in item 1.11 | - |
1.26 Explanation necessary for an understanding of the transactions
Payments represent directors' fees.
2.1 | Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows |
Nil | |
2.2 | Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest |
Nil | |
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
Amount available $A'000 | Amount used $A'000 | ||
3.1 | Loan facilities | - | - |
3.2 | Credit standby arrangements | - | - |
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. | Current quarter $A'000 | Previous quarter $A'000 | |
4.1 | Cash on hand and at bank | 3,073 | 3,373 |
4.2 | Deposits at call | - | 7 |
4.3 | Bank overdraft | - | - |
4.4 | Bank Accepted Commercial Bills and Term Deposits with maturity of less than 3 months | - | - |
Total: cash at end of quarter (item 1.23) | 3,073 | 3,380 | |
Acquisitions (Item 1.9(a)) | Disposals (Item 1.10(a)) |
Nil | Nil |
Name of entity
Place of incorporation or registration
Consideration for acquisition or disposal
Total net assets
Nature of business
QRxpharma Ltd. issued this content on 08 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 February 2016 00:40:29 UTC
Original Document: http://www.qrxpharma.com/IRM/PDF/1498/Appendix4CQuarterEnded30June2015
